EW News and Press, Edwards Lifesciences Corporation From 02/26/23

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended December 31, 2022, Baron Health Care Fund rose 9.08% (Institutional Shares) vs. the 11.54% gai...

Raymond James has downgraded Edwards Lifesciences ( NYSE: EW ) to market perform from outperform due to concerns over slowing growth for transcatheter aortic valve replacements (TAVR). The firm also withdrew its price target. Although TAVR are growing 8%-9%, that's not enough to m...

Summary Edwards Lifesciences has been in portfolios since 2017. Edwards' revenue rose over +40% from 2016 through 2021 driven by TAVR revenues that more than doubled. We estimate Edwards' addressable market for TAVR grows by about $1 billion per year in the U.S. alone, based on demo...

Summary Wedgewood Partners is a money manager founded in 1988 with the goal of providing investors with a superior approach to managing investment portfolios. The results for the typical investor in 2022 were likely worst still as many investors (including Wedgewood) had a meaningful we...

Edwards Lifesciences Corp (EW) Q4 2022 Earnings Conference Call January 31, 2023, 05:00 PM ET Company Participants Mark Wilterding - VP, IR Michael Mussallem - Chairman & CEO Scott Ullem - Corporate VP & CFO Bernard Zovighian - Corporate VP, Transcatheter M...

Edwards Lifesciences press release ( NYSE: EW ): Q4 Non-GAAP EPS of $0.64 beats by $0.03 . Revenue of $1.35B (+1.5% Y/Y) beats by $20M . Shares +2.3% . Q4 TAVR sales were flat; constant currency sales grew 5 percent Overall, the company is reaffirming the s...

Edwards Lifesciences ( NYSE: EW ) is scheduled to announce Q4 earnings results on Tuesday, January 31st, after market close. The consensus EPS Estimate is $0.61 (+19.6% Y/Y) and the consensus Revenue Estimate is $1.33B (flat Y/Y). Over the last 2 years, EW has beaten EPS est...

The shares of Edwards Lifesciences ( NYSE: EW ) fell more than ~1% pre-market Monday after Piper Sandler downgraded the heart device maker to Neutral from overweight, citing “a less-than-ideal stock set-up.” According to the analyst Adam Maeder, a physician survey in...

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 31, 2023 PR Newswire IRVINE, Calif. , Jan. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW ) plans to announce its operating results for the quarter ended December 31, 2022 aft...